Β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study. (February 2016)

• Record Type: Journal Article
• Authors: Nielsen, Peter Brønnum; Larsen, Torben Bjerregaard; Gorst-Rasmussen, Anders; Skjøth, Flemming; Lip, Gregory Y.H.
• Is Part Of: Circulation. Volume 9:Number 2(2016)
• Publication Date: 2016-02
• Subjects: atrial fibrillation -- cohort studies -- heart failure -- mortality -- prognosis; Heart failure -- Periodicals; 616.129005
• DOI: 10.1161/CIRCHEARTFAILURE.115.002597
• Languages: English
• ISSNs: 1941-3289

Abstract

Abstract : Background—: Recent data suggest that β-blockers are associated with prognostic advantages in heart failure (HF) patients without concomitant atrial fibrillation (AF), but not in HF patients with concomitant AF. We aimed to investigate associations between β-blocker treatment and cardiovascular outcome and mortality in AF patients with and without HF. Methods and Results—: Three nationwide registries were used to identify patients with nonvalvular AF patients with or without concomitant HF. Patients were stratified into β-blocker users and β-blocker nonusers, and according to the presence of a HF diagnosis. We followed the patients ⩽5 years after baseline. Six different cardiovascular outcomes were investigated, including all-cause mortality and fatal thromboembolic events. Crude event rates were ascertained and propensity-matched Cox regression was used to compare event rates according to β-blocker usage status. A total of 205 174 patients were included, where 39 741 patients had prevalent HF. In the latter subgroup of patients, the 1-year propensity-matched hazard ratio (HR) for all-cause mortality was 0.75 (95% confidence interval, 0.71–0.79; nontreated used as reference). For patients without concomitant HF, the propensity-matched HR for all-cause mortality was 0.78 (95% confidence interval, 0.71–0.76). Conclusions—: In this large nationwide cohort study, evidence of a lower mortality with β-blocker therapy in AF patients with concomitant HF was observed. In addition, this association was accompanied with indications that β-blocker treatment is also associated with a better prognosis in AF patients without concomitant HF. Abstract : Supplemental Digital Content is available in the text.